These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 16740723

  • 1. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 2. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K.
    Oncogene; 2007 Aug 23; 26(39):5793-807. PubMed ID: 17369857
    [Abstract] [Full Text] [Related]

  • 3. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M, Strebhardt K.
    Oncogene; 2002 May 09; 21(20):3162-71. PubMed ID: 12082631
    [Abstract] [Full Text] [Related]

  • 4. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.
    Cancer Biother Radiopharm; 2011 Aug 15; 26(4):427-36. PubMed ID: 21797676
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.
    Cancer Res; 2011 Aug 01; 71(15):5225-34. PubMed ID: 21642374
    [Abstract] [Full Text] [Related]

  • 12. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL.
    Cancer Res; 2002 Jul 15; 62(14):4132-41. PubMed ID: 12124352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ, Liu ZJ, Shimoi K, Zhu BT.
    Cancer Res; 2005 Jan 15; 65(2):387-93. PubMed ID: 15695378
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S.
    Cancer Res; 2001 Jun 15; 61(12):4892-900. PubMed ID: 11406568
    [Abstract] [Full Text] [Related]

  • 16. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D.
    Cancer; 2003 Oct 01; 98(7):1377-85. PubMed ID: 14508823
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.